NSCLC, Stage I Clinical Trial
— NEOpredictOfficial title:
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
NCT number | NCT04205552 |
Other study ID # | CA224-063 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 4, 2020 |
Est. completion date | June 2025 |
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | June 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection (Clinical stages I B, II and selected stage III A) - Eastern Cooperative Oncology Group (ECOG) = 1 - Sufficient pulmonary function to undergo curative lung cancer surgery - Adequate hematological, hepatic and renal function parameters: - Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) = 50% documented either by echocardiography or multigated acquisition scan (MUGA) - Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures Exclusion Criteria: - Active or history of autoimmune disease or immune deficiency - Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration - Subjects who have undergone organ transplant or allogeneic stem cell transplantation - Uncontrolled or significant cardiovascular disease - Patients with active neurological disease - Active malignancy or a prior malignancy within the past 3 years - Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication - Peripheral polyneuropathy NCI CTCAE Grade = 2 - History of gastric perforation or fistulae in past 6 months - Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment. - The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or implantation of a venous port-system. - Any other concurrent preoperative antineoplastic treatment including irradiation - Pregnant/Breastfeeding women - Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to prior immune therapy - Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent - Previous treatment with Nivolumab or Relatlimab |
Country | Name | City | State |
---|---|---|---|
Belgium | Jessa Hospital Hasselt | Hasselt | |
Germany | University Hospital Essen | Essen | |
Germany | Thoraxklinik Heidelberg gGmbH-Universitätsklinikum Heidelberg | Heidelberg | |
Netherlands | Netherlands Cancer Institute | Amsterdam |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Essen |
Belgium, Germany, Netherlands,
Schuler M, Cuppens K, Plones T, Wiesweg M, Du Pont B, Hegedus B, Koster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lahnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Neoadjuvant nivolumab wi — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg) | Within 43 days after first study medication | ||
Secondary | Estimation of pathological tumor response rate | Within 43 days after first study medication (day of surgery) | ||
Secondary | Estimation of curative (R0) resection rate | Within 43 days after first study medication (day of surgery) | ||
Secondary | Objective radiological response rate | Objective radiological response rate per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 | After 3, 6, 9 and 12 months post-surgery | |
Secondary | Disease-free survival rate at 12 months | Assessment of disease-free survival rate at 12 months per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 | 12 months | |
Secondary | Overall survival rate at 12 months | 12 months | ||
Secondary | Morbidity | Estimation of morbidity within 90 days after surgery | within 90 days after surgery | |
Secondary | Mortality | Estimation of mortality within 90 days after surgery | within 90 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05686434 -
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
|
Phase 2 | |
Recruiting |
NCT04317534 -
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
|
Phase 2 | |
Not yet recruiting |
NCT03446911 -
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06467383 -
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
|
||
Recruiting |
NCT04830826 -
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
|
||
Recruiting |
NCT06404164 -
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
|
N/A | |
Recruiting |
NCT03454685 -
The Role of Microbiota on the Development of Lung Cancer
|
||
Enrolling by invitation |
NCT06028412 -
Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
|
N/A | |
Recruiting |
NCT03446547 -
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
|
Phase 2 |